Chronic Myelogenous Leukemia in the Age of Targeted Therapy: Recommendations From an Expert Panel CME

Author Information and Disclosures

Release Date: June 30, 2008; Valid for credit through June 30, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

This program is based on a discussion by an expert panel convened at the American Society of Hematology Meeting, December 7, 2007, in Atlanta, Georgia.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 education | outcomes | science.
Novartis Oncology
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe the molecular pathogenesis of CML and the evolution of therapeutic options developed to treat patients with CML
  2. Analyze the advantages and disadvantages of current methods for testing and monitoring patients with CML
  3. Examine the latest clinical developments evaluating the use of targeted therapies for the treatment of patients with CML
  4. Assess current therapeutic approaches for the treatment of CML to maximize patient response to and compliance with targeted therapies
Authors and Disclosures

Jorge Cortes, MD
Disclosure: Dr. Cortes: Grants/research support: Bristol-Myers Squibb; Novartis; Wyeth.


Francis J Giles, MB, MD, FRCPI, FRCPath.
Disclosure: Dr. Giles: Grants/research support: Amgen; Bristol-Myers Squibb Company; Merck & Co., Inc.; Novartis; Pfizer Inc; Structural GenomiX.


John Goldman, DM, FRCP FMed Sci
Disclosure: Dr. Goldman: Honoraria from industry: Bristol-Myers Squibb Company; Novartis.


Andreas Hochhaus, MD
Disclosure: Dr. Hochhaus: Grants/research support: Bristol-Myers Squibb Company; Innovive Pharmaceuticals; Novartis; Wyeth.


Timothy Hughes, MD, MBBS
Disclosure: Dr. Hughes: Grants/research support: Bristol-Myers Squibb Company; Novartis.


Michael Mauro, MD
Disclosure: Dr. Mauro: Consultant: Bristol-Myers Squibb; Novartis.


Oliver Ottmann, MD
Disclosure: Dr. Ottmann: Advisory board member: Innovive Pharmaceuticals. Honoraria from industry: Bristol-Myers Squibb Company; Innovive Pharmaceuticals; Novartis. Grants/research support: Bristol-Myers Squibb Company; Novarits.


Jerald Radich, MD
Disclosure: Dr. Radich: Employment: Bristol-Myers Squibb; Novartis (lab support).
 
education | outcomes | science
education | outcomes | science is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

education | outcomes | science designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. The American Medical Association has determined that non-US licensed physicians who participate in this CME activity are eligible for AMA PRA Category 1 Credit™.

This activity was planned to address the ACGME/ABMS core competencies of patient care and medical knowledge.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.